Authors:
Booy R, Nolan T, Reynolds G, Richmond P, Nissen M, Marshall H, et al.
Authors notes:
Pediatric Infectious Disease Journal. 2015;34(12):1379-1384
Keywords:
Haemophilus influenzae type b, Neisseria meningitidis sero- group C, antibody persistence, toddlers, vaccines
Abstract:
Antibody persistence is evaluated in healthy Australian children four and five years post-vaccination with a single dose of combined Haemophilus influenzae type b - Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) compared to separately administered Hib-TT and MenC-CRM197 vaccines (Hib+MCC).
The according-to-protocol cohorts for persistence at Years 4 and 5 included 282 and 263 children, respectively.
The percentages of children with rSBA-MenC titers >1:8 at Years 4 and 5 were 12.5% and 19.0%, respectively, in the Hib-MenC group; and 12.3% and 25.0%, in the Hib+MCC group.
All children in each group had anti-PRP concentrations >0.15 μg/ml at Year 5.
Exploratory analyses suggested no potential differences between groups in rSBA-MenC or anti-PRP antibody persistence. No vaccine-related SAEs were reported.
Antibody persistence was similar for Years 4 and 5 after Hib-MenC-TT or Hib+MCC vaccination, with the majority of children retaining anti-PRP antibody concentrations >0.15 μg/ml at both timepoints.
The percentage of children retaining rSBA-MenC titers >1:8 was low (≤25%), suggesting that a MenC booster dose may be warranted before adolescence.